- CONDITION CENTERS
Roche (Nutley, NJ) and Glaxo-SmithKline (Research Triangle Park, NC) recently received FDA approval for Boniva Injectionthe first intravenous (IV) medication indicated for the treatment of postmenopausal osteoporosis. The product is a member of the bisphosphonate class, which is the most frequently prescribed medicine for osteoporosis. Boniva Injection, administered as a 15-to 30-second IV injection, will provide an alternative for patients who have difficulty with oral bisphosphonate dosing requirements. Furthermore, because the product will be administered once every 3 months by health care professionals, clinicians will have a greater awareness of patient compliance with therapy. Boniva Injection 3 mg/3 mL will be available in boxes containing one single- use, clear glass prefilled syringe, along with 1 needle and an alcohol swab. For more information, visit www.gsk.com or www.rocheusa.com.